Multiple Myeloma / USA / up to $55 / Ends June 2026
This study is for the US, to learn more about the experience of adults living with Multiple Myeloma and are familiar with CAR T Therapy.
Time & Location
20 Mar 2026, 19:00 – 23:00
Zoom
Study objectives
Medicys, in conjunction with Thermo Fisher Scientific, a research organization, is conducting an online research study called “US physician and patient experience with CAR-T cell therapy and bispecific antibodies in multiple myeloma” to better understand patient experiences with newer treatments for multiple myeloma, such as CAR-T cell therapy and bispecific antibodies. We are inviting adults in the United States who:
• Have been diagnosed with multiple myeloma, and
• Have been prescribed a CAR-T cell therapy or bispecific antibody treatment, whether or not you actually received it, in the past 12 months You may also qualify if you:
• Have completed or discontinued bispecific antibody therapy, or
• Did not respond to CAR-T treatment within the past year
